Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus FOLFOX-4 in First-line Metastatic Colorectal Cancer
NCT00125034Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of KL-140 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Best Overall Response Rate up to 1 year. Started Jul 2005; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00125034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125034.